SIRT6

Across TCGA pan-cancer cohorts, SIRT6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SIRT6 data layer compared with 29 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SIRT6 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SIRT6 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and GBM show a favorable association.

CCRCC, GBM, and PDAC are the cancer types where SIRT6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.964	0.826	.004	14	view →
GBM	OS	Median	All	0.937	0.774	.003	13	view →
PDAC	OS	Median	II,III,IV	0.705	0.969	<.001	12	view →
UCEC	DFS	Median	All	1.000	0.940	.034	2	view →
LUAD	DFS	Tertile	All	0.736	0.374	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SIRT6–CCRCC (OS)

Open the CCRCC breakdown →